Companies ›Healthcare ›IPD.AX

IPD.AX — ASX Advanced Medical Equipment & Technology

Ipd.Ax

A$0,01

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-182,4 %

ROE

-113,4 %

Net margin

-182,6 %

Debt / equity

0,71

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

IPD.AX is a company in the Healthcare sector, specializing in Advanced Medical Equipment & Technology, and generates revenue primarily through the development and sale of medical equipment and technology solutions.

Business. IPD.AX is a company in the Healthcare sector, specializing in Advanced Medical Equipment & Technology, and generates revenue primarily through the development and sale of medical equipment and technology solutions.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY4 analysts

4 buy0 hold0 sell

Avg 12m price target0,05

Analyst recommendations

4 analysts · consensus Buy

Buy4

Hold0

Sell0

12-month price target

0,05

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

4 analysts · indicative

Ownership

—

not yet wired

Profitability→

-113,4 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning IPD.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to IPD.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

IPD.AX has a liquidity position that is relatively strong, with a current ratio of 4.86, indicating that the company has more than four times as many current assets as current liabilities. However, the company's operating cash flow is negative at -14.65 million AUD, and its free cash flow is also negative at -19.66 million AUD, suggesting that the company is not generating sufficient cash from operations to fund its activities.

Profitability metrics for IPD.AX are negative, with a return on equity of -113.37% and a return on assets of -55.78%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's operating income is negative at -23.21 million AUD, and its net income is also negative at -23.24 million AUD, further highlighting the company's unprofitable operations.

The company's revenue concentration is not disclosed in the provided data, and there is no information on the geographic distribution of its revenue. However, the company's operations are primarily focused on the Advanced Medical Equipment & Technology industry, and there is no indication of significant diversification across segments or geographies.

The growth trajectory of IPD.AX is not clearly defined in the provided data, as there are no specific numeric deltas or revenue history provided for the current or next fiscal year. The company's negative operating and net income suggest that it is not currently experiencing growth and may be facing operational challenges.

The risk assessment for IPD.AX indicates a low level of liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags, and the company's debt-to-equity ratio is 0.71, which is relatively low. However, the company's negative cash flows and unprofitable operations may pose long-term risks to its financial stability.

Recent events related to IPD.AX are not detailed in the provided data. The company's financial snapshot and valuation metrics suggest that it is currently facing financial challenges, but there is no specific information on recent filings or transcripts that would provide further insight into the company's operations or strategic direction.

Key takeaways

IPD.AX has a strong current ratio but is experiencing negative operating and free cash flows.
The company's profitability metrics are negative, indicating unprofitable operations.
There is no information on revenue concentration or geographic exposure.
The company's growth trajectory is not clearly defined, and it is currently unprofitable.
The risk assessment indicates low liquidity and dilution risk, but the company's financial stability may be at risk due to its negative cash flows and unprofitable operations.
margin_outlook_rationale: The company's negative operating and net income suggest that its margins are currently unprofitable, and there is no indication of improvement in the near term.
rd_outlook_rationale: There is no specific information on the company's research and development activities or their impact on future profitability.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

A$0,01

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

A$20.5M

Net cashⓘ

A$7.2M

Current ratioⓘ

4.9

Debt / equityⓘ

0.7

ROAⓘ

-55.8%

ROEⓘ

-1.1%

Cash conversionⓘ

63.0%

CapEx / revenueⓘ

-7.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,01

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-03 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,01
Revenue	—no estimate	—no estimate	17,0M AUD
Operating income	—no estimate	—no estimate	-19,5M AUD

Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy2

Buy2

Hold0

Sell0

Strong sell0

12-month price targetA$0,05 · Median A$0,05

Low A$0,03High A$0,06

Operating income · consensus-19,5M AUD

EPS surprise

+9,1 %

reported vs consensus · beat

Revenue surprise

−25,0 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowA$0,03

MeanA$0,05

MedianA$0,05

HighA$0,06

SpotA$0,01

+691.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-182,4 %Bottom quartile

Net Margin-182,6 %Bottom quartile

ROE-113,4 %Bottom quartile

Capex / Rev-7,8 %Below median

D/E0,71Bottom quartile

Cash Conv0,63Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

IPD.AX Market data — financials · 2026-05-28
ImpediMed Ltd Market data — analyst estimates · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

IPD.AXCanonical

ASX · AUD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread